| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 69,900 | 44,600 | -300 | 59,100 |
| Depreciation and amortization | 116,100 | 76,600 | 36,300 | 118,700 |
| Non-cash lease expense | 29,100 | 19,500 | 9,600 | 29,200 |
| Non-cash interest expense, net | -6,200 | -4,000 | -2,500 | -4,800 |
| Equity-based compensation expense | 17,000 | 14,400 | 7,600 | 27,100 |
| Net loss on disposals, consolidations and deconsolidations | -19,000 | -3,400 | -6,400 | -21,500 |
| Loss on debt extinguishment | -1,300 | 0 | - | -5,100 |
| Deferred income taxes | 3,300 | -1,800 | -300 | 10,300 |
| Equity in earnings of unconsolidated affiliates, net of distributions received | -1,000 | -200 | -1,100 | -300 |
| Accounts receivable | 7,700 | -8,500 | -4,800 | 31,200 |
| Medicare accelerated payments and deferred governmental grants | - | - | - | 0 |
| Other operating assets and liabilities | 84,300 | 82,100 | 61,700 | 56,200 |
| Net cash provided by operating activities | 170,900 | 87,300 | 6,000 | 188,700 |
| Purchases of property and equipment | 65,900 | 46,100 | 22,700 | 68,100 |
| Payments for acquisitions, net of cash acquired | 52,600 | 48,000 | 44,000 | 291,200 |
| Proceeds from disposals of facilities and other assets | 42,900 | 42,900 | 4,800 | 1,500 |
| Purchases of equity investments | 13,400 | 3,800 | 3,800 | 1,700 |
| Proceeds from sales of equity investments | 0 | 0 | - | 4,000 |
| Other investing activities | 31,500 | 19,300 | 10,700 | 21,300 |
| Net cash used in investing activities | -120,500 | -74,300 | -76,400 | -376,800 |
| Principal payments on long-term debt | 460,400 | 299,400 | 119,300 | 1,108,800 |
| Borrowings of long-term debt | 510,100 | 382,200 | 213,600 | 1,463,800 |
| Payments of debt issuance costs | 1,600 | 0 | - | 15,100 |
| Distributions to non-controlling interest holders | 168,800 | 116,300 | 62,300 | 122,400 |
| Proceeds related to ownership transactions with non-controlling interest holders | 2,500 | 3,100 | 1,700 | 5,600 |
| Other financing activities | 1,700 | -2,000 | -3,500 | -9,100 |
| Net cash (used in) provided by financing activities | -116,500 | -32,400 | 30,200 | 214,000 |
| Net (decrease) increase in cash and cash equivalents | -66,100 | -19,400 | -40,200 | 25,900 |
| Cash and cash equivalents at beginning of period | 269,500 | 269,500 | 269,500 | 195,900 |
| Cash and cash equivalents at end of period | 203,400 | 250,100 | 229,300 | 221,800 |
Surgery Partners, Inc. (SGRY)
Surgery Partners, Inc. (SGRY)